Neuronetics Inc (STIM)
3.54
+0.36 (+11.32%)
USD |
NASDAQ |
Jul 07, 13:32
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 94.77M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -78.01% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 1.627 |
| Price to Book Value | 1.237 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.4627 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
News
Headline
Wire
Time (ET)
Yahoo
06/27 07:43
Yahoo
05/27 07:20
Yahoo
05/17 08:31
MT Newswires
05/12 07:36
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 08/03/2022* | -- | Results | Q2 2022 | -- | -0.41 | -- | |
| 08/03/2022* | 08:30 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 05/12/2022 | -- | Results | Q1 2022 | -0.41 | -0.40 | -3.36% | |
| 05/12/2022 | 08:30 EST | Earnings Call | Q1 2022 | -- | -- | -- | |
| 03/08/2022 | -- | Results | Q4 2021 | -0.29 | -0.32 | 9.38% | |
| 03/08/2022 | 08:30 EST | Earnings Call | Q4 2021 | -- | -- | -- | |
| 11/09/2021 | -- | Results | Q3 2021 | -0.31 | -0.30 | -2.65% | |
| 11/09/2021 | 08:00 EST | Earnings Call | Q3 2021 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options. |
| URL | https://www.neurostar.com |
| Investor Relations URL | http://ir.neuronetics.com/ |
| HQ State/Province | Pennsylvania |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Aug. 03, 2022 (est.) |
| Last Earnings Release | May. 12, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of July 06, 2022.
Fundamentals
| Revenue (TTM) | 57.20M |
| Total Expenses (TTM) | 88.00M |
| Net Income (TTM) | -34.15M |
| Total Assets (Quarterly) | 129.94M |
| Total Liabilities (Quarterly) | 53.35M |
| Shareholders Equity (Quarterly) | 76.60M |
| Cash from Operations (TTM) | -31.00M |
| Cash from Investing (TTM) | -10.24M |
| Cash from Financing (TTM) | 0.795M |
Ratings
Profile
Edit
| Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options. |
| URL | https://www.neurostar.com |
| Investor Relations URL | http://ir.neuronetics.com/ |
| HQ State/Province | Pennsylvania |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Aug. 03, 2022 (est.) |
| Last Earnings Release | May. 12, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Morningstar | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| STIM Tweets |